Mithat Gönen, PhD

Chief, Biostatistics Service

Mithat Gönen, PhD

Chief, Biostatistics Service
Mithat Gönen


Texas Tech University

Current Research Interest 

Dr. Gönen has been at MSK since 1999 and has been serving as Chief of the Biostatistics Service since 2015. His translational and clinical collaborations focus on diagnosis, treatment and surveillance of gastrointestinal cancers. Most of Dr. Gönen’s methodological research originates from these collaborations, including building, assessing and comparing prognostic and predictive models, design and analysis of clinical trials, as well as Bayesian methods. He is the principal investigator of the MSK MIND Colorectal Project, and the MSK PI of the multi-center VOL-PACT project. Dr. Gönen served as co-director of the AACR/ASCO Vail Workshop on Methods in Clinical Cancer Research from 2011 to 2013 and served ASCO and AACR in numerous other roles. He served the Society for Clinical Trials (SCT) in various roles: President, Board Member, Program Chair and Deputy Editor of its journal, Clinical Trials: Journal of the Society for Clinical Trials. Dr. Gönen is a fellow of the American Statistical Association, a fellow of the SCT, a member of the board of reviewing editors for Science in Translational Medicine, a member of the EORTC Protocol Review Committee, and a member of NHLBI’s DSMB for the RECOVER-CT program. He served the International Biometric Society as the Program Chair for its North American Region meeting in 2015.


Selected peer-reviewed publications:

  1. Capanu M, Giurcanu M, Begg CB, Gönen M. Subsampling based variable selection for generalized linear models. Comput Stat Data Anal. 2023 Aug;184:107740. doi: 10.1016/j.csda.2023.107740. Epub 2023 Mar 11. PMID: 37090139; PMCID: PMC10118238.
  2. Leitao MM Jr, Kreaden US, Laudone V, Park BJ, Pappou EP, Davis JW, Rice DC, Chang GJ, Rossi EC, Hebert AE, Slee A, Gonen M. The RECOURSE Study: Long-term Oncologic Outcomes Associated With Robotically Assisted Minimally Invasive Procedures for Endometrial, Cervical, Colorectal, Lung, or Prostate Cancer: A Systematic Review and Meta-analysis. Ann Surg. 2023 Mar 1;277(3):387-396. doi: 10.1097/SLA.0000000000005698. Epub 2022 Sep 8. PMID: 36073772; PMCID: PMC9905254.
  3. Ecker BL, Lee J, Saadat LV, Aparicio T, Buisman FE, Balachandran VP, Drebin JA, Hasegawa K, Jarnagin WR, Kemeny NE, Kingham TP, Groot Koerkamp B, Kokudo N, Matsuyama Y, Portier G, Saltz LB, Soares KC, Wei AC, Gonen M, D’Angelica MI. Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis. Lancet Oncol. 2022 Oct;23(10):1332-1342. doi: 10.1016/S1470-2045(22)00506-X. Epub 2022 Sep 1. PMID: 36058227.
  4. Mitchell AP, Mishra Meza A, Trivedi NU, Bach PB, Gönen M. Physician Payments from Pharmaceutical Companies Related to Cancer Drugs. Oncologist. 2022 Oct 1;27(10):857-863. doi: 10.1093/oncolo/oyac160. Erratum in: Oncologist. 2023 May 8;28(5):e315. PMID: 35946837; PMCID: PMC9526499.
  5. Weiser MR, Chou JF, Keshinro A, Chapman WC Jr, Bauer PS, Mutch MG, Parikh PJ, Cercek A, Saltz LB, Gollub MJ, Romesser PB, Crane CH, Shia J, Markowitz AJ, Garcia-Aguilar J, Gönen M; Colorectal Cancer Disease Management Team of Memorial Sloan Kettering Cancer Center. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. JAMA Netw Open. 2021 Nov 1;4(11):e2133457. doi: 10.1001/jamanetworkopen.2021.33457. Erratum in: JAMA Netw Open. 2022 Jan 4;5(1):e2147251. PMID: 34748003; PMCID: PMC8576585. 

Visit PubMed for a full listing of Mithat Gönen’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Mithat Gönen discloses the following relationships and financial interests:

  • GLG Pharmaceuticals
    Professional Services and Activities
  • Guidepoint Global Advisors
    Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures